In recent years, the important role of UGT enzymes in the metabolic elimination of drugs or their phase I metabolites has been increasingly deciphered, which will provide more opportunities for deeply understanding clinical drug (herb)–drug interaction or drug-induced metabolic disorders of endogenous substances (Dong et al., 2012). This evidence concerns the gene SLC35A2 and metabolic disease.